Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma: BENCART Trial

NCT02424045 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT02424045
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02424045 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma: BENCART Trial
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2015
Completion date
September 30, 2017
Enrollment
30 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

t-cell lymphoma